Medication info
Neurocaba-PGI Capsule 75mg (Pregabalin)

Neurocaba-PGI Capsule 75mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Samjin Pharmaceutical Co., Ltd.
Appearance
A hard capsule with a brown upper part and white lower part filled with white to light yellow powder
Packaging
Domestically available - 30 capsules/bottle, Domestically available - 100 capsules/bottle, for export - 30 capsules/box[((10 capsules/PTP)*3)]
Approval status
Active

MFDS item code 201108892 · Approved 2011.10.21 · Insurance code 647803580

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive therapy for partial seizures of epilepsy
Who takes it
Adults · Children
Adult dose
This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function (see section ‘5. Patients with renal impairment’). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be started at a dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: This medicine may be started at a dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered (see section ‘4. Discontinuation’). 2. Epilepsy Adults: This medicine may be started at a dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg daily. The starting dose is 75 mg twice daily (150 mg daily), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies were also conducted at a dose of 600 mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation Based on current clinical experience, if this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys unchanged. The clearance of this medicine is directly affected by creatinine clearance; therefore, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. Creatinine clearance (ml/min)* This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily pregabalin dose should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Dosage regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60: 150, 600, BID or TID ≥30 -<60: 75, 300, BID or TID ≥15 -<30: 25-50, 150, QD or BID <15: 25, 75, QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under dosage regimen. b: The supplemental dose is an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (aged 65 years or older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Samjin Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive therapy for partial seizures of epilepsy

  • Peripheral neuropathic pain
  • central neuropathic pain
  • secondary generalized symptoms
  • partial seizures
  • fibromyalgia
View approved original text

This medicine is used for the treatment of peripheral and central neuropathic pain in adults. It is also prescribed as an adjunct for partial seizures in epilepsy patients with or without secondary generalized symptoms. Finally, it is effective in the treatment of fibromyalgia. It helps to alleviate symptoms of these conditions and improve quality of life.

How to take

Adult dose

This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function (see section ‘5. Patients with renal impairment’). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be started at a dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: This medicine may be started at a dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered (see section ‘4. Discontinuation’). 2. Epilepsy Adults: This medicine may be started at a dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg daily. The starting dose is 75 mg twice daily (150 mg daily), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies were also conducted at a dose of 600 mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation Based on current clinical experience, if this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys unchanged. The clearance of this medicine is directly affected by creatinine clearance; therefore, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. Creatinine clearance (ml/min)* This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily pregabalin dose should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Dosage regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60: 150, 600, BID or TID ≥30 -<60: 75, 300, BID or TID ≥15 -<30: 25-50, 150, QD or BID <15: 25, 75, QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under dosage regimen. b: The supplemental dose is an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (aged 65 years or older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors; therefore, if there are any changes in mood or behavior during treatment, consult a doctor immediately. Those with hypersensitivity to this drug should not take it, and diabetic patients may need to adjust the dosage of blood glucose control medications due to weight gain. If symptoms of angioedema occur, such as swelling of the face or neck due to allergic reactions, it should be stopped immediately. Elderly patients are at risk of falls due to dizziness or drowsiness, so special caution should be exercised at the beginning of treatment. Some patients may experience blurred vision or changes in vision, which may improve upon discontinuation of the medication. If this medication is suddenly discontinued, withdrawal symptoms such as insomnia, headache, anxiety, and depression may appear; therefore, it should be gradually tapered under a doctor's supervision. Due to the risk of drug abuse, those with a history of substance abuse or mental disorders should inform their doctor beforehand. Patients with impaired kidney function may require dosage adjustments. Patients with severe heart diseases should use this drug with caution, as concomitant use with opioid analgesics may enhance central nervous system depression. Those with respiratory or neurological conditions, or the elderly, may be at a higher risk of severe respiratory depression and may require dosage adjustments. In early pregnancy, there is a risk of fetal malformations, so use during pregnancy should be avoided, and women of childbearing age should use effective contraceptive methods. Breastfeeding women should discontinue nursing while taking this medication, as it can be passed into breast milk and affect the baby. When engaging in risky activities such as driving or operating machinery, caution should be taken due to the risk of accidents caused by dizziness and drowsiness. If severe rashes or blisters appear on the skin while taking this medication, it should be stopped immediately and a doctor consulted. In case of overdose, symptoms such as confusion, drowsiness, depression, and seizures may occur; treatment such as hemodialysis may be necessary.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • swelling around the mouth
  • upper airway swelling
  • dizziness
  • drowsiness
Show 181 more
  • loss of consciousness
  • confusion
  • mental disorder
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • sadness
  • thoughts of suicide
  • pain
  • seizures
  • sweating
  • misuse
  • abuse
  • dependence
  • withdrawal symptoms
  • rhinitis
  • neutropenia
  • increased appetite
  • appetite loss
  • hypoglycemia
  • confusion
  • spatial disorientation
  • irritability
  • feeling of relief
  • decreased libido
  • depersonalization
  • dysesthesia
  • agitation
  • mood swings
  • emotional blunting
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • impulsivity
  • apathy
  • ataxia
  • coordination abnormalities
  • balance disorders
  • amnesia
  • attention deficit
  • memory impairment
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensory loss
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disturbances
  • fasciculations
  • decreased reflexes
  • motor abnormalities
  • psychomotor agitation
  • postural dizziness
  • hypersensitivity
  • burning sensation
  • intention tremor
  • syncope
  • confusion
  • motor retardation
  • olfactory abnormalities
  • loss of taste
  • writing disorder
  • diplopia
  • vertigo
  • hyperacusis
  • first-degree AV block
  • tachycardia
  • bradycardia
  • tachyarrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • abdominal bloating
  • excessive salivation
  • gastroesophageal reflux
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasm
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urinary disturbances
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • breast discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falling
  • feeling intoxicated
  • sensory disturbances
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increase in alanine aminotransferase
  • increase in serum creatine phosphokinase
  • increase in aspartate aminotransferase
  • increase in blood glucose
  • decrease in platelet count
  • decrease in serum potassium
  • weight loss
  • increase in serum creatinine
  • decrease in white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • congestive heart failure
  • pulmonary edema
  • tongue swelling
  • itchiness
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • states of confusion
  • agitation
  • restlessness
  • worsening of spasms
  • shock
  • anaphylaxis-like symptoms
  • skin and mucous membrane syndrome
  • erythema multiforme

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine should be stored in a tightly closed container to protect it from air and moisture. The storage temperature should be maintained between 15 to 30 degrees Celsius.

Appearance and packaging

Appearance

A hard capsule with a brown upper part and white lower part filled with white to light yellow powder

Package unit

Domestically available - 30 capsules/bottle, Domestically available - 100 capsules/bottle, for export - 30 capsules/box[((10 capsules/PTP)*3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.